Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30008495HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059013HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059014HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059015HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059016HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059017HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059018HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059019HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059020HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TVIS30059021HIVENSG00000121879.6protein_codingPIK3CAYesNo5290P42336
Q4LE51
TCGA Plot Options
Drug Information
GenePIK3CA
DrugBank IDDB12483
Drug NameCopanlisib
Target IDBE0002379
UniProt IDP42336
Regulation Typeinhibitor
PubMed IDs30147333; 29127587
CitationsMensah FA, Blaize JP, Bryan LJ: Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. Onco Targets Ther. 2018 Aug 13;11:4817-4827. doi: 10.2147/OTT.S142264. eCollection 2018.@@Markham A: Copanlisib: First Global Approval. Drugs. 2017 Dec;77(18):2057-2062. doi: 10.1007/s40265-017-0838-6.
GroupsApproved; Investigational
Direct ClassificationQuinazolinamines
SMILESCOC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21
Pathways
PharmGKB
ChEMBLCHEMBL3218576